Brain Metastasis in Renal Cell Carcinoma Patients

2011 ◽  
pp. 53-61 ◽  
Author(s):  
Aida Loudyi ◽  
Wolfram E. Samlowski
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell

Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study

2019 ◽  
Vol 17 (6) ◽  
pp. e1163-e1170 ◽  
Author(s):  
Alfredo Suarez-Sarmiento ◽  
Kevin A. Nguyen ◽  
Jamil S. Syed ◽  
Adam Nolte ◽  
Kamyar Ghabili ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals BRAIN METASTASIS FROM RENAL CELL CARCINOMA

1984 ◽  
Vol 75 (2) ◽  
pp. 278-282
Author(s):  
Fujio Masuda ◽  
Yoshikazu Arai ◽  
Tetsuro Ohnishi ◽  
Jyojiro Nakada ◽  
Masayasu Suzuki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell

68Ga-PSMA PET/CT to Distinguish Brain Metastasis of Renal Cell Carcinoma From Radiation Necrosis After Stereotactic Radiosurgery

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nuh Filizoglu ◽  
Ilknur Alsan Cetin ◽  
Tugba Nergiz Kissa ◽  
Khanim Niftaliyeva ◽  
Tunc Ones
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Stereotactic Radiosurgery ◽  
Renal Cell ◽  
Radiation Necrosis ◽  
Psma Pet ◽  
Pet Ct

scholarly journals Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2875
Author(s):  
Yoshiyuki Matsui
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

In patients with renal cell carcinoma, brain metastasis is generally one of the poor prognostic factors. However, the recent introduction of molecular target therapy and immune checkpoint inhibitor has remarkably advanced the systemic treatment of metastatic renal cell carcinoma and prolonged the patients’ survival. The pivotal clinical trials of those agents usually excluded patients with brain metastasis. The incidence of brain metastasis has been increasing in the actual clinical setting because of longer control of extra-cranial disease. Brain metastasis subgroup data from the prospective and retrospective series have been gradually accumulated about the risk classification of brain metastasis and the efficacy and safety of those new agents for brain metastasis. While the local treatment against brain metastasis includes neurosurgery, stereotactic radiosurgery, and conventional whole brain radiation therapy, the technology of stereotactic radiosurgery has been especially advanced, and the combination with systemic therapy such as molecular target therapy and immune checkpoint inhibitor is considered promising. This review summarizes recent progression of multimodality treatment of brain metastasis of renal cell carcinoma from literature data and explores the future direction of the treatment.

scholarly journals Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma

Cancer ◽  
2011 ◽  
Vol 117 (21) ◽  
pp. 4958-4965 ◽  
Author(s):  
Jonathan Verma ◽  
Eric Jonasch ◽  
Pamela Allen ◽  
Nizar Tannir ◽  
Anita Mahajan
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitors

Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 340-340
Author(s):  
J. Verma ◽  
E. Jonasch ◽  
P. Allen ◽  
N. M. Tannir ◽  
A. Mahajan
Keyword(s):  
Renal Cell Carcinoma ◽  
Multivariate Analysis ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Lung Metastasis ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Risk Category ◽  
Tki Treatment ◽  
Initial Staging

340 Background: Tyrosine kinase inhibitors (TKIs) have been shown to improve overall survival (OS) in metastatic renal cell carcinoma (mRCC) but their effect on brain metastasis (BM) development is unclear. The purpose of our study is to evaluate the impact of TKIs on incidence of BM and OS in patients with mRCC. Methods: Searched the M. D. Anderson Cancer Center (MDACC) tumor registry for patients who presented with mRCC in 2002-2003 and 2006-2007 with no BM at initial staging. The following items were retrospectively collected: age, sex, Fuhrman grade, sites of disease, nephrectomy, systemic therapy including TKIs (sorafenib or sunitinib), MSKCC risk category, BM treatment, and vital status. Interaction between OS and incidence of BM and these variables was estimated using the Cox proportional hazards model. OS and incidence of BM were estimated using the Kaplan-Meier (K-M) method. Results: 338 patients were identified; 154 (46%) were treated with a TKI prior to BM, and 184 (54%) were not. There were no significant differences in age, histology, involved sites of disease other than lung, nephrectomy, or MSKCC risk category between the groups. A higher proportion of the nonTKI group received other systemic agents and had lung metastasis at initial staging (p=0.03). Median OS was longer in the TKI-treated group (25 months versus 12.1 months, p<0.0001). In Cox multivariate analysis, TKI treatment (HR=0.53, 95% CI 0.38-0.74, p<0.001) was associated with improved OS and lung/mediastinal involvement and ECOG performance status > 2 (HR 1.87, 95% CI 1.28-2.71, p=0.001) were associated with poor OS. Median OS after BM was not significantly different between TKI treated and untreated groups. 44 patients (13%) developed a BM, including 29 (15.8%) of the nonTKI group and 15 (9.7%) of the TKI group. In K-M analysis, the 5-year incidence of BM was 40% versus 17% respectively (logrank p<0.001). In Cox multivariate analysis, TKI treatment was associated with lower incidence of BM (HR=0.39, 95% CI 0.21-0.73, p=0.003). Lung metastasis increased the risk of BM (HR=9.61, 95% CI 2.97-31.1, p<0.001). Conclusions: Treatment with TKI agents reduces the incidence of BM in mRCC. Lung metastasis is a risk factor for BM development. No significant financial relationships to disclose.

Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis

2015 ◽  
Vol 13 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Diogo A. Bastos ◽  
Ana M. Molina ◽  
Vaios Hatzoglou ◽  
Xiaoyu Jia ◽  
Susanne Velasco ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Safety And Efficacy

MP-5.06: Clinical Follow-Up Study of Brain Metastasis of Renal Cell Carcinoma

Urology ◽  
2008 ◽  
Vol 72 (5) ◽  
pp. S93
Author(s):  
H. Rhew ◽  
C. Sul ◽  
J. Rim ◽  
H. Kim ◽  
B. Sung ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Follow Up Study
Sign in / Sign up

Export Citation Format

Share Document